Log in
Producers of dietary supplements have historically lacked scientific rigour when advertising the health benefits of their products. Researchers at Cardiff University have addressed this problem in relation to omega-3 polyunsaturated fatty acids (PUFAs). They identified a family of enzymes (aggrecanases) as key players in the onset of arthritis, knowledge subsequently used to identify a specific subset of omega-3-PUFAs with beneficial activity in a canine arthritis model. This led to novel patents and product development in both the pet food and human dietary supplement markets. These include the patented use of omega-3 PUFAs in Hills'® Prescription Diet® range and the development and marketing of Seven Seas' `JointCare' products.
Canine osteoarthritis affects up to 20% of adult dogs and is of worldwide welfare importance. Research by the University of Liverpool (UoL) (with collaborators) has led to profound changes in the ways in which veterinarians manage canine and feline osteoarthritis. Molecular insights have led to new prescription diets that enable veterinarians to improve the health and wellbeing of companion animals and have provided economic impact through sales of these prescription diets. In addition, a new clinical metrology instrument (`Liverpool Osteoarthritis in Dogs' or "LOAD") for assessment of canine osteoarthritis by veterinarians and owners has changed veterinary practice through improved diagnosis, monitoring and management of dogs with osteoarthritis. LOAD has been licensed on a global basis to a pharmaceutical company (Novartis Animal Health).
A Cardiff researcher has led an International 15 year programme resulting in multiple novel findings which have led to changes in the recommended diagnosis and treatment of acquired haemophilia A (AHA). The research has, for the first time, allowed the comparison of immunosuppressive regimens for inhibitor eradication and comparison of the efficacy of treatment strategies to control bleeds. Studies led directly to the production of UK and International guidelines on the management of AHA with 14 of the 18 specific recommendations in the UK guideline being underpinned by Cardiff-led research.
Southampton research has been central to the development and international licensing of one of only two novel asthma therapies in the last 30 years, transforming asthma control and survival for severe allergic asthmatics.
Key studies by the Southampton Group have underpinned the development of immunoglobulin (Ig)-E as a key therapeutic target for controlling allergic asthma, with the Southampton-led first-in- man safety and efficacy trials critical to the registration of the anti-IgE therapy, omalizumab.
This contribution also generated significant inward investment in UK R&D and opened up wider investigation of anti-IgE therapy in a broad range of atopic and inflammatory indications.
Research by a team at Southampton into amyloid beta protein (A03b2) immunisation to treat Alzheimer's disease has been key to changing the way the global medical community understands and reacts to the disease. The first to observe that A03b2 immunisation clears A03b2 plaques, the team's studies were pivotal in initiating and informing the safe clinical trial development of 40 immunotherapy agents; investments of $3bn by the pharmaceutical industry; and 30 phase II and phase III studies. The research shaped US government policy on new safety measures for clinical trials and played a leading role in the doubling of UK funding to tackle Alzheimer's.
Since 2011, an estimated 3 million UK milk consumers have benefitted each year from research conducted at the University of Reading, which has helped reduce saturated fatty acids (SFAs) in milk and milk products. The research, which was carried out between 2004 and 2013, manipulated dairy cows' diets to produce milk with reduced saturated fat and increased unsaturated fat content. Leading UK retailer, Marks and Spencer (M&S), used this research to support its suppliers in providing a new diet regime for their dairy cows, launching a new low saturated fat M&S milk in October 2011. The launch of this healthier milk product has led to (i) improved diets and reduced associated health risks (heart disease, obesity and cancer) for M&S customers (ii) reduced use of non-sustainable palm oil in cow diets (iii) reduced harmful greenhouse gas emissions (iv) increased sales for M&S and enhanced reputation in terms of quality and corporate social responsibility (v) increased payment contracts for milk producers and (vi) new techniques to measure fatty acids in milk for the dairy industry.
Dietary fat plays an important role in the causation of cardiovascular disease (CVD). Using randomized controlled trials of dietary fat modification, King's College London researchers have provided information about the effects of specific fatty acids on CVD risk which the Food Standards Agency have used to inform its policy decisions and future research strategy. The research also contributed to the development of international guidelines on the intakes of specific types of fatty acids and helped the food industry reformulate fats to be low in trans fatty acids. This research has also had an impact on dietary advice given by health professionals, the media and patient groups.
Impact: Health and welfare, policy and clinical practice; randomised trial evidence has changed the management and outcome of acute coronary syndromes (ACS) globally.
Significance: Advanced anti-platelet and revascularisation therapies have become standards of care worldwide. There have been large (10-50%) reductions in the death rate from coronary heart disease across Europe. Clopidogrel was the second best-selling drug in the USA in 2011.
Beneficiaries: Patients with ACS, clinical practitioners, NHS and healthcare delivery organisations, policy-makers, pharmaceutical companies.
Attribution: Building on prior studies, Fox (UoE) and colleagues led multicentre randomised controlled trials; international trials were co-chaired by Fox with international investigators.
Reach: Global; guideline changes in Europe and USA; applies to the up to 5% of the population who have ACS.
This case study outlines the impact of novel omega-3 fatty acid therapy for sickle cell disease on health and policy. 128 patients on the treatment since 2010, and another 300 who started to receive it in June 2012 have seen remarkable improvements in health and quality of life as assessed by reductions in hospital admission and absence from work/school due to the disease. A panel of experts set up by the Ministry of Health of Sudan to evaluate the evidence recommended the integration of the therapy in the management of the disease in a policy report dated December 20, 2012. The Ministry has accepted the recommendation.
Research carried out at the University of Southampton has led to the development of a new tool for detecting and managing malnutrition. The Malnutrition Universal Screening Tool (MUST) has been rolled out to more than 80% of hospitals and care homes in England and 98% in Scotland, is part of national health policy in Finland and the Netherlands, and has attracted interest internationally. The National Institute for Health and Clinical Excellence bases its current quality standard for nutritional support in adults on the MUST framework; only two NICE guidelines have saved the NHS more money. MUST has become an integral part of the UK's health policy framework, embedded in routine clinical care and supported by bodies responsible for clinical and care excellence. It is central to learning programmes on managing malnutrition.